Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to ...

Prostate cancer screenings slash the risk of dying from the disease in the following decades, according to new research. The screening measures the amount of prostate-specific antigen (PSA) in men’s ...

Screening men for prostate cancer would save thousands of lives by slashing their risk of dying from the disease by 13 per cent, a major study reveals. Testing led to a ‘sustained reduction’ in deaths ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide ...

Wolinsky is a Chicago-based medical journalist and publisher of The Active Surveillor, a Substack newsletter that covers lower-risk prostate cancer and active surveillance. In 2002, at age 55, I ...

A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...

The National Institute for Health and Care Excellence (NICE) has recommended a new oral treatment for men with untreated hormone-relapsed metastatic prostate cancer. NICE assessed evidence from the ...